CORT - NASDAQ
Corcept Therapeutics Incorporated
$74.97
+5.0%Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
At a Glance
Live SnapshotCorcept Therapeutics Incorporated Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
Corcept Therapeutics Incorporated Cash Flow Statement
CORT • NASDAQ
| Corcept Therapeutics Incorporated Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
98.2M | 141.2M | 106.1M | 101.4M | 112.5M | 106M | 94.2M | 75.4M | 129.1M | 8.1M | -6.4M | -31.4M | -46M | -38M | -32.4M | -26M | -20.2M | -20.1M | -11.6M | -24.9M | |
1.9M | 1.3M | 2.4M | 3.4M | 3.1M | 2.2M | 2.2M | 236K | 106K | 87K | 155K | 141K | 74K | 27K | 3K | 6K | 10K | 12K | 13K | 14K | |
0.0 | -40.2M | -29.5M | -33.9M | 4.3M | 14.1M | 16.9M | 14.1M | -76.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.1M | 0.0 | |
84.5M | 61.4M | 48.9M | 42.4M | 42.9M | 33.5M | 29.3M | 23.7M | 13.4M | 7.1M | 6M | 5.2M | 5.2M | 5.3M | 3.4M | 2.1M | 1.8M | 1.6M | 1.1M | 0.0 | |
-15M | -10.9M | -9.1M | 1.4M | 5.1M | 1.5M | -1.7M | -1.7M | 763K | 2M | 2.9M | 3.7M | 4.4M | 1.7M | 0.0 | 0.0 | 16K | 1.3M | 1.1M | 1.6M | |
(0.0) | (60.3M) | (47.6M) | (39.7M) | (9.1M) | (10.9M) | (6.7M) | (1.4M) | (377K) | (40K) | (57K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-27.6M | 45.3M | 8.2M | 5.5M | -57K | -5.4M | -4.7M | 3.9M | -5.7M | 1.2M | 500K | -5M | -762K | -5M | 1.5M | 1.6M | 373K | -1.2M | -464K | 68K | |
142M | 198.1M | 127M | 120.3M | 167.9M | 152M | 136.1M | 115.7M | 60.9M | 18.4M | 3.1M | -27.4M | -37.1M | -36M | -27.4M | -22.3M | -18M | -18.4M | -11M | -23.2M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-211K | -2.2M | -139K | -413K | -469K | -1.2M | -1.1M | -298K | -419K | -194K | -17K | -174K | -127K | -151K | -25K | (0.0) | -7K | -7K | (0.0) | -1.3M | |
(0.0) | (0.0) | (0.0) | (0.0) | -136.6M | (118M) | (116.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-319.6M | -588.3M | -328.7M | -355.1M | -312.8M | -420.1M | -299M | -233.1M | -73M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -3.6M | -3.6M | -6.4M | (0.0) | |
389.6M | 412.9M | 419.8M | 241.2M | 449.4M | 302.1M | 182.3M | 142.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6M | 5.9M | 1M | 26.7M | |
0.0 | 0.0 | 0.0 | 0.0 | 136.6M | -118M | -116.7M | -90.5M | -73M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6M | 0.0 | 0.0 | 0.0 | |
(69.8M) | -177.6M | (90.9M) | -114.3M | (136.1M) | -119.3M | -117.8M | -90.8M | -73.5M | -194K | -17K | -174K | -127K | -151K | -25K | (0.0) | (3.6M) | (2.3M) | -5.4M | (25.4M) | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-245.9M | -6M | -145.4M | 0.0 | -296M | -9.9M | -31M | -23.7M | 0.0 | 0.0 | 0.0 | 0.0 | 55K | 0.0 | 42.5M | 23M | 23.5M | 19.3M | 18.9M | 2.9M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -15.1M | -14.8M | -9.2M | -4.9M | 0.0 | 29.9M | 0.0 | -6K | -10K | -13K | -13K | -12K | |
-245.9M | -15.7M | -145.4M | (0.0) | -296M | -9.9M | -31M | -23.7M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
25.5M | -22.3M | -3.3M | -17.3M | -6.6M | 22.2M | 2.3M | 9.3M | 7.2M | 7.7M | 22.3M | 1.8M | -1M | 59.7M | 0.0 | 0.0 | 0.0 | 0.0 | 18K | 43K | |
-220.4M | -28.3M | -148.7M | -17.3M | -302.6M | 12.2M | -28.6M | -14.3M | -8M | -7.1M | 13.1M | -3.1M | -970K | 89.6M | 42.5M | 23M | 23.5M | 19.3M | 18.9M | 3M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
1.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-7.2M | -7.9M | 69.2M | -11.3M | 1.4M | 44.9M | -10.4M | 10.6M | -20.5M | 11.1M | 16.2M | -30.6M | -38.2M | 53.4M | 15.1M | 711K | 9.2M | 3.3M | 2.5M | 5.1M | |
127.7M | 135.6M | 66.3M | 77.6M | 76.2M | 31.3M | 41.6M | 31.1M | 51.5M | 40.4M | 24.2M | 54.9M | 93M | 39.6M | 24.6M | 23.9M | 14.7M | 11.4M | 8.9M | 3.8M | |
120.5M | 127.7M | 135.6M | 66.3M | 77.6M | 76.2M | 31.3M | 41.6M | 31.1M | 51.5M | 40.4M | 24.2M | 54.9M | 93M | 39.6M | 24.6M | 23.9M | 14.7M | 11.4M | 8.9M | |
141.8M | 195.9M | 126.9M | 119.9M | 167.4M | 150.7M | 135M | 115.4M | 60.5M | 18.2M | 3.1M | -27.6M | -37.2M | -36.2M | -27.4M | -22.3M | -18M | -18.4M | -11M | -24.6M |
SEC Filings
CORT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 03, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 28, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 30, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | April 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 22, 2026 | 2026 |
Related Guides
Continue your CORT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.